当前位置: 首页 >> 检索结果
1081. Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2, Update Alert).
作者: Isolde Sommer.;Andreea Iulia Dobrescu.;Emma Persad.;Martin Fangmeyer.;Irma Klerings.;Gerald Gartlehner.
来源: Ann Intern Med. 2024年177卷8期e2400141页 1082. Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort Study.
作者: Tracey G Simon.;Daniel E Singer.;Yichi Zhang.;Julianna M Mastrorilli.;Alexander Cervone.;Elyse DiCesare.;Kueiyu Joshua Lin.
来源: Ann Intern Med. 2024年177卷8期1028-1038页
Apixaban, rivaroxaban, and warfarin have shown benefit for preventing major ischemic events, albeit with increased bleeding risk, among patients in the general population with atrial fibrillation (AF). However, data are scarce in patients with cirrhosis and AF.
1084. In adults with AMI who are at risk for HF, empagliflozin did not reduce a composite of first HF hospitalization or all-cause death at 18 mo.
Butler J, Jones WS, Udell JA, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390:1455-1466. 38587237.
1085. Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study.
作者: Joshua Petimar.;Jessica G Young.;Han Yu.;Sheryl L Rifas-Shiman.;Matthew F Daley.;William J Heerman.;David M Janicke.;W Schuyler Jones.;Kristina H Lewis.;Pi-I D Lin.;Carly Prentice.;John W Merriman.;Sengwee Toh.;Jason P Block.
来源: Ann Intern Med. 2024年177卷8期993-1003页
Antidepressants are among the most commonly prescribed medications, but evidence on comparative weight change for specific first-line treatments is limited.
1086. Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease : A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical Trials.
作者: Elaine Ku.;Lesley A Inker.;Hocine Tighiouart.;Charles E McCulloch.;Ogechi M Adingwupu.;Tom Greene.;Raymond O Estacio.;Mark Woodward.;Dick de Zeeuw.;Julia B Lewis.;Thierry Hannedouche.;Tazeen H Jafar.;Enyu Imai.;Giuseppe Remuzzi.;Hiddo J L Heerspink.;Fan Fan Hou.;Robert D Toto.;Philip K Li.;Mark J Sarnak.
来源: Ann Intern Med. 2024年177卷7期953-963页
In patients with advanced chronic kidney disease (CKD), the effects of initiating treatment with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) on the risk for kidney failure with replacement therapy (KFRT) and death remain unclear.
1087. In device-detected AF, DOACs vs. aspirin or placebo reduce ischemic stroke and increase major bleeding.
McIntyre WF, Benz AP, Becher N, et al. Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. Circulation. 2024;149:981-988. 37952187.
1088. In patients with the kidney-dysfunction triad, facilitated evidence-based care did not reduce hospitalizations at 1 y.
Vazquez MA, Oliver G, Amarasingham R, et al; ICD-Pieces Study Group. Pragmatic trial of hospitalization rate in chronic kidney disease. N Engl J Med. 2024;390:1196-1206. 38598574.
1090. mRNA COVID-19 vaccination during pregnancy was not linked to increased adverse neonatal outcomes.
Norman M, Magnus MC, Söderling J, et al. Neonatal outcomes after COVID-19 vaccination in pregnancy. JAMA. 2024;331:396-407. 38319332.
1091. Effect of Acupuncture on Neurogenic Claudication Among Patients With Degenerative Lumbar Spinal Stenosis : A Randomized Clinical Trial.
作者: Lili Zhu.;Yuanjie Sun.;Jing Kang.;Jun Liang.;Tongsheng Su.;Wenbin Fu.;Wei Zhang.;Rongshui Dai.;Yan Hou.;Hong Zhao.;Weina Peng.;Weiming Wang.;Jing Zhou.;Ruimin Jiao.;Biyun Sun.;Yan Yan.;Yan Liu.;Zhishun Liu.
来源: Ann Intern Med. 2024年177卷8期1048-1057页
Acupuncture may improve degenerative lumbar spinal stenosis (DLSS), but evidence is insufficient.
1093. In adults with COVID-19 and severe hypoxemia, lower vs. higher oxygenation targets increased days alive without life support.
Nielsen FM, Klitgaard TL, Siegemund M, et al; HOT-COVID Trial Group. Lower vs higher oxygenation target and days alive without life support in COVID-19: the HOT-COVID randomized clinical trial. JAMA. 2024;331:1185-1194. 38501214.
1094. In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo.
Rech J, Tascilar K, Hagen M, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403:850-859. 38364841.
1095. In T1DM without CVD, the LIFE-T1D model predicted lifetime risk for CVD and non-CVD mortality.
Helmink MAG, Hageman SHJ, Eliasson B, et al. Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: the LIFE-T1D model. Diabetes Obes Metab. 2024;26:2229-2238. 38456579.
1096. In many mental health and some somatic disorders, efficacy of therapist-guided remote CBT and in-person CBT does not differ.
Zandieh S, Abdollahzadeh SM, Sadeghirad B, et al. Therapist-guided remote versus in-person cognitive behavioural therapy: a systematic review and meta-analysis of randomized controlled trials. CMAJ. 2024;196:E327-E340. 38499303.
1097. In women with epilepsy, use of valproate in the second half of pregnancy was linked to autism in offspring.
Hernández-Díaz S, Straub L, Bateman BT, et al. Risk of autism after prenatal topiramate, valproate, or lamotrigine exposure. N Engl J Med. 2024;390:1069-1079. 38507750.
1098. In grade C/D erosive esophagitis, vonoprazan ranks highest among PPIs and P-CABs for healing and maintaining remission.
Zhuang Q, Chen S, Zhou X, et al. Comparative efficacy of P-CAB vs proton pump inhibitors for grade C/D esophagitis: a systematic review and network meta-analysis. Am J Gastroenterol. 2024;119:803-813. 38345252.
1099. Association of Medicare Advantage Enrollment With Financial Burden of Care : A Retrospective Cohort Study.
Compared with traditional Medicare (TM), Medicare Advantage (MA) plans typically offer supplemental benefits and lower copayments for in-network services and must include an out-of-pocket spending limit.
|